GlassScriptPhysician profile
Diego Escobosa
NPI 1710054598
$1,268.17
in general payments reported to CMS, 2019-2025
22 companies · $13.84 in 2025
The $13.84 reported for 2025 was less than what a typical Adolescent Medicine (Pediatrics) provider received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $104 · 2021: $344 · 2022: $64.04 · 2024: $201 · 2025: $13.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $214.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $250.57 | 2021 | |
| Ironshore Pharmaceuticals INC. | $164.08 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $135.37 | 2019-2025 | Relexxii |
| Neos Therapeutics, LP | $128.00 | 2019-2020 | |
| Tris Pharma INC | $73.39 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.08 | 2019-2021 | |
| Shire North American Group INC | $53.28 | 2019 | |
| Pfizer INC. | $49.37 | 2019-2021 | |
| Cranial Technologies, INC | $47.56 | 2019 | |
| Adlon Therapeutics L.P. | $46.08 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $45.66 | 2024 | Rexulti |
| Cumberland Pharmaceuticals, INC. | $31.72 | 2019 | |
| Corium, LLC | $24.03 | 2024 | Azstarys |
| Vyne Pharmaceuticals INC. | $23.56 | 2020 | |
| Noven Therapeutics, LLC | $22.27 | 2024 | Xelstrym |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $21.21 | 2019 | |
| Sanofi Pasteur INC. | $18.41 | 2019 | |
| Glaxosmithkline, LLC. | $17.85 | 2020 | |
| Arbor Pharmaceuticals, INC. | $17.21 | 2019 | |
| Merck Sharp & Dohme LLC | $14.61 | 2019 | |
| Phadia US INC. | $14.15 | 2022 | |
| Seqirus USA INC | $13.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diego Escobosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.